Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast

Loss of constitutive activity is correlated with increased thermostability of the human adenosine A2Areceptor

(2013) Nicolas Bertheleme et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation

(2013) K Pabreja et al.   BRITISH JOURNAL OF PHARMACOLOGY

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

Quantitative analysis of human ras localization and function in the fission yeastSchizosaccharomyces pombe

(2013) Michael Bond et al.   YEAST

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Pancreatitis: A Potential Complication of Liraglutide?

(2012) Andrea S Franks et al.   ANNALS OF PHARMACOTHERAPY

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

(2012) D. A. Scott et al.   DIABETES OBESITY & METABOLISM

Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea

(2012) S. Seino   DIABETOLOGIA

Targeting the glucagon receptor family for diabetes and obesity therapy

(2012) Young Min Cho et al.   PHARMACOLOGY & THERAPEUTICS

Quantifying Ligand Bias at Seven-Transmembrane Receptors

(2011) S. Rajagopal et al.   MOLECULAR PHARMACOLOGY

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use

(2010) Sarah L Anderson et al.   ANNALS OF PHARMACOTHERAPY

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

(2010) K. W. Sloop et al.   DIABETES

Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent "Compound 2" at the GLP-1 Receptor

(2010) K. Coopman et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening

(2010) C. Koole et al.   MOLECULAR PHARMACOLOGY

GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes

(2009) Jens Juul Holst et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Determination of Adenosine A1 Receptor Agonist and Antagonist Pharmacology Using Saccharomyces cerevisiae: Implications for Ligand Screening and Functional Selectivity

(2009) G. D. Stewart et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes

(2008) K. W. Figueroa et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS